AEMD Key Statistics, Chart & Performance
The current stock price of AEMD is 3.72 USD. In the past month the price decreased by -14.29%. In the past year, price decreased by -87.03%.
AEMD Latest News, Press Relases and Analysis
AEMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.56 | 213.10B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.57 | 197.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.42 | 137.42B | ||
| SYK | STRYKER CORP | 26.86 | 135.30B | ||
| BDX | BECTON DICKINSON AND CO | 13.76 | 56.63B | ||
| IDXX | IDEXX LABORATORIES INC | 55.66 | 56.04B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.65 | 48.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.4 | 38.48B | ||
| RMD | RESMED INC | 25.4 | 36.71B | ||
| DXCM | DEXCOM INC | 36.32 | 26.35B | ||
| PODD | INSULET CORP | 64.59 | 20.77B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.51 | 18.45B |
Related stock screener links
About AEMD
Company Profile
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Company Info
AETHLON MEDICAL INC
11555 Sorrento Valley Road, Suite 203
San Diego CALIFORNIA 92123 US
CEO: Charles J. Fisher Jr
Employees: 9
Phone: 16199410360
AETHLON MEDICAL INC / AEMD FAQ
Can you describe the business of AETHLON MEDICAL INC?
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
What is the stock price of AETHLON MEDICAL INC today?
The current stock price of AEMD is 3.72 USD. The price increased by 6.59% in the last trading session.
What is the dividend status of AETHLON MEDICAL INC?
AEMD does not pay a dividend.
How is the ChartMill rating for AETHLON MEDICAL INC?
AEMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of AEMD stock?
AETHLON MEDICAL INC (AEMD) has a market capitalization of 2.83M USD. This makes AEMD a Nano Cap stock.
Can you provide the upcoming earnings date for AETHLON MEDICAL INC?
AETHLON MEDICAL INC (AEMD) will report earnings on 2026-02-10.
Can you provide the ownership details for AEMD stock?
You can find the ownership structure of AETHLON MEDICAL INC (AEMD) on the Ownership tab.
AEMD Technical Analysis
AEMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AEMD. AEMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AEMD Financial Highlights
Over the last trailing twelve months AEMD reported a non-GAAP Earnings per Share(EPS) of -102.34. The EPS increased by 54.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -153.74% | ||
| ROE | -195.94% | ||
| Debt/Equity | 0 |
AEMD Forecast & Estimates
7 analysts have analysed AEMD and the average price target is 12.62 USD. This implies a price increase of 239.31% is expected in the next year compared to the current price of 3.72.